BRPI0508231A - medicamentos e métodos para tratar a dor de cabeça - Google Patents

medicamentos e métodos para tratar a dor de cabeça

Info

Publication number
BRPI0508231A
BRPI0508231A BRPI0508231-5A BRPI0508231A BRPI0508231A BR PI0508231 A BRPI0508231 A BR PI0508231A BR PI0508231 A BRPI0508231 A BR PI0508231A BR PI0508231 A BRPI0508231 A BR PI0508231A
Authority
BR
Brazil
Prior art keywords
headache
botulinum toxin
methods
medication
medicines
Prior art date
Application number
BRPI0508231-5A
Other languages
English (en)
Inventor
Catherine C Turkel
Mitchell F Brin
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/789,180 external-priority patent/US9078892B2/en
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0508231A publication Critical patent/BRPI0508231A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MEDICAMENTOS E MéTODOS PARA TRATAR A DOR DE CABEçA. A presente invenção refere-se a um distúrbio de uso excessivo de medicação para a dor aguda (tal como um distúrbio de uso excessivo de medicação para dor de cabeça) pode ser tratado pela administração de uma toxina botulínica a um paciente. Uma dor de cabeça pode ser tratada mais eficazmente pela co-administração de uma toxina botulínica e um medicamento de triptano a um paciente e/ou a eficácia de uma medicação de triptano pode ser aumentada. A toxina botulínica pode ser a toxina botulínica tipo A e a toxina botulínica pode ser administrada à ou na vicinidade de onde um paciente experimenta ou é predisposto a experimentar dor ou uma dor de cabeça.
BRPI0508231-5A 2004-02-26 2005-02-15 medicamentos e métodos para tratar a dor de cabeça BRPI0508231A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/789,180 US9078892B2 (en) 2004-02-26 2004-02-26 Methods for treating pain and for treating a medication overuse disorder
US11/039,506 US20050191321A1 (en) 2004-02-26 2005-01-18 Methods for treating headache
PCT/US2005/004778 WO2005082339A2 (en) 2004-02-26 2005-02-15 Medicaments and methods for treating headache

Publications (1)

Publication Number Publication Date
BRPI0508231A true BRPI0508231A (pt) 2007-07-17

Family

ID=34914767

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508231-5A BRPI0508231A (pt) 2004-02-26 2005-02-15 medicamentos e métodos para tratar a dor de cabeça

Country Status (16)

Country Link
US (10) US20050191321A1 (pt)
EP (3) EP2752197B1 (pt)
JP (1) JP4913721B2 (pt)
KR (1) KR20060126793A (pt)
CN (1) CN103251937B (pt)
AU (2) AU2005216887A1 (pt)
BR (1) BRPI0508231A (pt)
CA (2) CA2557588C (pt)
CY (1) CY1115104T1 (pt)
DK (1) DK1725253T3 (pt)
ES (1) ES2460731T3 (pt)
MX (1) MX337511B (pt)
PL (1) PL1725253T3 (pt)
PT (1) PT1725253E (pt)
SI (1) SI1725253T1 (pt)
WO (1) WO2005082339A2 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
US7311666B2 (en) 2004-07-10 2007-12-25 Trigeminal Solutions, Inc. Apparatus for collecting information
WO2006078588A2 (en) * 2005-01-18 2006-07-27 Allergan, Inc. Improved methods for treating headache
US7749515B2 (en) * 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7655244B2 (en) * 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
AU2012241076B2 (en) * 2005-02-01 2015-05-14 Allergan, Inc. Targeted delivery of Botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
FR2889936B1 (fr) 2005-09-01 2007-12-21 Sod Conseils Rech Applic Methode pour quantifier une neurotoxine cholinergique dans un echantillon
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US20080103546A1 (en) * 2006-10-27 2008-05-01 Cyberonics, Inc. Patient management system for treating epilepsy using an implantable medical device
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) * 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US8940308B2 (en) 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
CN103813802A (zh) 2011-07-14 2014-05-21 阿勒根公司 用于治疗与性活动相关的失禁的方法
US8491917B1 (en) 2012-03-12 2013-07-23 William J. Bender Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the head
DK2849781T3 (en) 2012-03-12 2017-10-16 William J Binder TREATMENT OF MIGRINE HEAD PAIN WITH PRESYNAPTIC NEUROTOXIN
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2836193B1 (en) 2012-04-13 2018-01-31 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (ii)
EP2919807B1 (en) * 2012-11-16 2018-07-11 Finzi, Eric Treatment of post-traumatic stress disorder using botulinum toxin a
BR112015024221A2 (pt) 2013-03-22 2017-07-18 Lipotec Sa exopolissacarídeo, uso do exopolissacarídeio, e, composição cosmética ou dermofarmacêutica
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
EP3068423B8 (en) 2013-11-12 2026-03-25 Healis Therapeutics, Inc. Treatment of panic disorder using botulinum toxin
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
WO2016149092A1 (en) 2015-03-13 2016-09-22 Allergan, Inc. Improved injection paradigm for administration of botulinum toxins
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
US10456419B2 (en) 2017-02-27 2019-10-29 Payman Sadeghi Method for treating migraine headaches
US10932711B2 (en) 2017-02-27 2021-03-02 Payman Sadeghi Method and system for neurohydrodissection
EP3600385A4 (en) * 2017-03-22 2021-04-07 Bonti, Inc. BOTULINUM NEUROTOXINS FOR THE TREATMENT OF TRAUMATIC INJURIES
EP3644971A4 (en) * 2017-06-26 2021-03-31 Bonti, Inc. CLOSTRIDIAL NEUROTOXIN FORMULATIONS AND USE
US20230210963A1 (en) * 2020-03-18 2023-07-06 Revance Therapeutics, Inc. Injectable botulinum toxin methos for treating headaches
CN116096399A (zh) 2020-06-03 2023-05-09 米奥托克斯有限责任公司 用于治疗偏头痛病症的区带性和靶向方法和用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
ES2332905T3 (es) * 1993-12-28 2010-02-15 Allergan, Inc. Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos.
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
PT1086702E (pt) * 1994-05-09 2005-08-31 William J Binder Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5670181A (en) * 1995-10-20 1997-09-23 Stokes; Christine P. Apparatus and method for slip casting for ceramic objects
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
EP1128844B1 (en) * 1998-10-27 2006-01-04 Mayo Foundation For Medical Education And Research Botulinum toxins for enhancing wound healing
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
ATE519494T1 (de) * 2000-02-08 2011-08-15 Allergan Inc Pharmazeutische zusammensetzungen mit botulinum- toxin
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US7226605B2 (en) 2001-07-27 2007-06-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
DE10150415A1 (de) 2001-10-11 2003-05-15 Andres O Ceballos-Baumann Arzneimittel zur Prophylaxe und Therapie von Depressionen
KR20040094756A (ko) * 2002-03-01 2004-11-10 엘란 파마슈티칼스, 인크. 신경 포착 증후군의 치료 방법
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
ES2381091T3 (es) * 2003-03-06 2012-05-23 Botulinum Toxin Research Associates, Inc. Tratamiento del dolor facial crónico y cefalea relacionados con la sinusitis con toxina botulínica
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609113B2 (en) * 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) * 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8048423B2 (en) 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US7270287B2 (en) 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US8512984B2 (en) * 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) * 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US7655244B2 (en) * 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) * 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
TWI282083B (en) * 2005-05-27 2007-06-01 Innolux Display Corp Backlight on/off control circuit
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
CA2620202C (en) * 2005-08-26 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) * 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
CA2823974A1 (en) * 2010-01-08 2011-07-14 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of migraine headaches
US8940308B2 (en) * 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
CN103813802A (zh) * 2011-07-14 2014-05-21 阿勒根公司 用于治疗与性活动相关的失禁的方法
US8491917B1 (en) * 2012-03-12 2013-07-23 William J. Bender Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the head
AU2013242906A1 (en) * 2012-04-03 2014-10-23 Basf Se Hair cosmetic composition which comprises a plant lecithin
US9005628B2 (en) * 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US10119638B2 (en) * 2013-02-06 2018-11-06 Agilent Technologies, Inc. Fluidic coupling devices, assemblies, and related methods
WO2014130581A1 (en) * 2013-02-20 2014-08-28 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
AU2015253045B2 (en) * 2014-04-30 2020-07-16 Allergan, Inc. Formulations of biologics for intravesical instillation
WO2016040039A1 (en) * 2014-09-12 2016-03-17 Allergan, Inc. Methods for treating osteoarthritis pain
WO2016149092A1 (en) * 2015-03-13 2016-09-22 Allergan, Inc. Improved injection paradigm for administration of botulinum toxins

Also Published As

Publication number Publication date
US20060121057A1 (en) 2006-06-08
AU2011201107A1 (en) 2011-04-07
US20170128552A1 (en) 2017-05-11
US8889151B2 (en) 2014-11-18
US20050191321A1 (en) 2005-09-01
WO2005082339A2 (en) 2005-09-09
US7704511B2 (en) 2010-04-27
JP4913721B2 (ja) 2012-04-11
US20100189655A1 (en) 2010-07-29
CN103251937A (zh) 2013-08-21
PT1725253E (pt) 2014-05-06
ES2460731T3 (es) 2014-05-14
WO2005082339A3 (en) 2005-12-01
CN103251937B (zh) 2015-10-07
AU2011201107B2 (en) 2012-12-20
US9555085B2 (en) 2017-01-31
US10092631B2 (en) 2018-10-09
SI1725253T1 (sl) 2014-05-30
US10603366B2 (en) 2020-03-31
DK1725253T3 (da) 2014-07-07
AU2005216887A1 (en) 2005-09-09
PL1725253T3 (pl) 2014-08-29
US9078893B2 (en) 2015-07-14
US20150313974A1 (en) 2015-11-05
MX337511B (es) 2016-03-09
EP1725253A2 (en) 2006-11-29
CY1115104T1 (el) 2016-12-14
EP1725253B1 (en) 2014-04-09
EP2433643A1 (en) 2012-03-28
KR20060126793A (ko) 2006-12-08
CA2557588C (en) 2017-11-28
HK1098072A1 (en) 2007-07-13
CA2557588A1 (en) 2005-09-09
US20090263426A1 (en) 2009-10-22
HK1199403A1 (en) 2015-07-03
US20200230217A1 (en) 2020-07-23
US20190038726A1 (en) 2019-02-07
EP2752197A1 (en) 2014-07-09
JP2007525505A (ja) 2007-09-06
EP2433643B1 (en) 2015-12-02
EP2752197B1 (en) 2019-11-20
US20060104995A1 (en) 2006-05-18
CA2982313A1 (en) 2005-09-09
US20220088157A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
BRPI0508231A (pt) medicamentos e métodos para tratar a dor de cabeça
Hylands-White et al. An overview of treatment approaches for chronic pain management
Assael et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial
BRPI0708640A8 (pt) composição farmacêutica, e, métodos para tratar um paciente com dor de cabeça de enxaqueca, para tratar um paciente com dor e para tratar um paciente com enxaqueca
Harden Pharmacotherapy of complex regional pain syndrome
BRPI0903464B8 (pt) formulação aquosa de um agente terapêutico e método para criar um dispositivo de aplicação de fármacos
BR0316906A (pt) administração do capsaicinoides
Choi et al. Topical agents: a thoughtful choice for multimodal analgesia
BRPI0410041A (pt) métodos para tratamento de dor de cabeça de sinusite
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
MX2019007779A (es) Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe).
BRPI0512311A (pt) uso de meloxicam em medicina veterinária para o tratamento de doenças inflamatórias dolorosas
Miranda et al. Synergism between NSAIDs in the orofacial formalin test in mice
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
ATE440598T1 (de) Analgesische zusammensetzung von topisch angewendeten, nichtsteroiden und entzündungshemmenden arzneimitteln und opioiden
BRPI0720500A8 (pt) Preparação líquida transdérmica
BR0006024A (pt) Composição para o tratamento de inflamação e dor em mamìferos
PL2043637T3 (pl) Sposoby i leki do podawania ibuprofenu
AR052047A1 (es) Metodos de uso y composiciones comprendiendo moduladores de pde4 para el tratamiento prevencion y control de inflamacion de las vias respiratorias
BRPI0607536A2 (pt) tratamento de dor
BR0211936A (pt) Uso de glicosamina e de um inibidor seletivo para ciclooxigenase-2, ou de pró-droga dos mesmos, na fabricação de um medicamento, bem como composição farmacêutica e kit compreendendo os mesmos
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
US9687518B2 (en) Medicament for treating muscle and skeletal diseases
BR112022025900A2 (pt) Formulações tópicas de (1s)-1-fenil-2-piridin-2-iletanamina
Pritchard et al. Streptozocin-diabetic rats show reduced hyperthermic effects but maintained anti-allodynia responses to the TRPV1 antagonist ABT-102 throughout nine days of dosing

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL